Form 4: VYNE Therapeutics Chief Scientific Officer Reports Stock Transaction
SEC Form 4 Filing
Iain Stuart, Chief Scientific Officer of VYNE Therapeutics, reports a transaction involving the withholding of shares to cover tax obligations related to vesting restricted stock units.
Summary
- On July 1, 2024, Iain Stuart, the Chief Scientific Officer of VYNE Therapeutics Inc., had 138 shares of common stock withheld by the issuer to satisfy tax withholding requirements.
- The price per share for the transaction was $1.92.
- Following the transaction, Stuart directly owns 133,603 shares of VYNE Therapeutics Inc.
Sentiment
Score: 7
Explanation: The document reflects a routine transaction related to executive compensation and tax obligations, which is neutral to slightly positive as it indicates ongoing equity-based compensation.
Industry Context
Form 4 filings are standard practice for reporting changes in beneficial ownership by company insiders, providing transparency to investors.
Stakeholder Impact
- The transaction has a minor impact on shareholders as it involves a small number of shares withheld for tax purposes.
Key Dates
| Date | Description |
|---|---|
| 07/01/2024 | Date of the stock transaction where shares were withheld for tax obligations. |
| 07/03/2024 | Date of signature for the Form 4 filing. |
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.